Title: A4447 1R
Official Title: 
Number of Sections: 1
Source: versions - Reprint SJU 9/26/24 1R
Media Type: text/html

================================================================================

Section 1:
A4447 1R [First Reprint] ASSEMBLY, No. 4447 STATE OF NEW JERSEY 221st LEGISLATURE INTRODUCED JUNE 3, 2024 Sponsored by: Assemblywoman  LUANNE M. PETERPAUL District 11 (Monmouth) Assemblyman  CHRISTOPHER P. DEPHILLIPS District 40 (Bergen, Essex and Passaic) Assemblyman  JOHN V. AZZARITI JR., M.D. District 39 (Bergen) Senator  RAJ MUKHERJI District 32 (Hudson) Senator  HOLLY T. SCHEPISI District 39 (Bergen) Co-Sponsored by: Assemblyman Conaway, Assemblywoman Speight, Senator O'Scanlon, Assemblywoman Flynn and Assemblyman Scharfenberger SYNOPSIS Allows certain health care practitioners referrals to pharmacies to be made in accordance with certain professional standards. CURRENT VERSION OF TEXT As reported by the Senate Judiciary Committee on September 26, 2024, with amendments. An Act concerning health care practitioner referrals and amending P.L.1989, c.19. Be It Enacted by the Senate and General Assembly of the State of New Jersey: 1. Section 2 of P.L.1989, c.19 (C.45:9-22.5) is amended to read as follows: 2. a.  A practitioner shall not refer a patient or direct an employee of the practitioner to refer a patient to a health care service in which the practitioner, or the practitioner's immediate family, or the practitioner in combination with the practitioner's immediate family has a significant beneficial interest [;]except [that,] as follows: (1) in the case of a practitioner, a practitioner's immediate family, or a practitioner in combination with the practitioner's immediate family who had the significant beneficial interest prior to the effective date of P.L.1991, c.187 (C.26:2H-18.24 et al.) [, and] ; (2) in the case of a significant beneficial interest in a health care service that provides lithotripsy or radiation therapy pursuant to an oncological protocol that was held prior to the effective date of this section of P.L.2009, c.24 [,] ; and (3) in the case of a practitioner, a practitioner's immediate family, or a practitioner in combination with the practitioner's immediate family who 1[had] has1 a significant beneficial interest in a pharmacy 1[and whose application for a permit to operate a pharmacy site was approved prior to the effective date of this section] that is integrated with an oncology practice, that only dispenses medications exclusively to patients of that practice, and that complies with the additional requirements set forth in subsection d. of this section1, the practitioner may continue to refer a patient or direct an employee to do so if that practitioner discloses the significant beneficial interest to the patient. b. If a practitioner is permitted to refer a patient to a health care service pursuant to this section, the practitioner shall provide the patient with a written disclosure form, prepared pursuant to section 3 of P.L.1989, c.19 (C.45:9-22.6), and post a copy of this disclosure form in a conspicuous public place in the practitioner's office. c. The restrictions on referral of patients established in this section shall not apply to: (1) medical treatment or a procedure that is provided at the practitioner's medical office and for which a bill is issued directly in the name of the practitioner or the practitioner's medical office; (2) renal dialysis; (3) ambulatory surgery or procedures involving the use of any anesthesia performed at a surgical practice licensed by the Department of Health pursuant to subsection g. of section 12 of P.L.1971, c.136 (C.26:2H-12) or at an ambulatory care facility licensed by the Department of Health to perform surgical and related services or lithotripsy services, if the following conditions are met: (a) the practitioner who provided the referral personally performs the procedure; (b) the practitioner's remuneration as an owner of or investor in the practice or facility is directly proportional to the practitioner's ownership interest and not to the volume of patients the practitioner refers to the practice or facility; (c) all clinically-related decisions at a facility owned in part by non-practitioners are made by practitioners and are in the best interests of the patient; and (d) disclosure of the referring practitioner's significant beneficial interest in the practice or facility is made to the patient in writing, at or prior to the time that the referral is made, consistent with the provisions of section 3 of P.L.1989, c.19 (C.45:9-22.6); (4) medically-necessary intraoperative monitoring services rendered during a neurosurgical, neurological, or neuro-radiological surgical procedure that is performed in a hospital; (5) a value-based arrangement made in accordance with 42 C.F.R. 411.357(aa), a payment model authorized under a Medicare shared savings program pursuant to 42 U.S.C. s.1395jjj, or a demonstration operated by the Center for Medicare and Medicaid Innovation established pursuant to at 42 U.S.C. s.1315a; and (6) Referrals that a practitioner makes, or directs an employee of the practitioner to make, to a health care service in which the referring practitioner has a significant beneficial interest, when participants in an alternative payment model registered with the Department of Health pursuant to section 3 of P.L.2017, c.111 (C.45:9-22.5c) make a bona fide determination that: the significant beneficial interest is reasonably related to the alternative payment model standards filed with the Department of Health, provided that the determination is documented and retained for a period of 10 years; and the referral is made in accordance with alternative payment model standards and professional standards applicable to the health care service in which the referring practitioner has a significant beneficial interest. 1d. The exemption set forth in paragraph (3) of subsection a. of this section shall apply to a pharmacy that is integrated with an oncology practice, provided that the pharmacy: (1) has direct access to the oncology practices patient records; (2) communicates with each patient in person or via telemedicine to review the prescription instructions and assesses the patient for interactions with other drugs and food; (3) synchronously consults with the oncology practices treating physicians as appropriate; and (4) complies with the requirements for timely delivery of medications, hours of operation, and recordkeeping that are established by rule or regulation by the State Board of Pharmacy.1 (cf: P.L.2021, c.347) 2.  This act shall take effect immediately.


================================================================================

Raw Text:
A4447 1R [First Reprint] ASSEMBLY, No. 4447 STATE OF NEW JERSEY 221st LEGISLATURE INTRODUCED JUNE 3, 2024 Sponsored by: Assemblywoman  LUANNE M. PETERPAUL District 11 (Monmouth) Assemblyman  CHRISTOPHER P. DEPHILLIPS District 40 (Bergen, Essex and Passaic) Assemblyman  JOHN V. AZZARITI JR., M.D. District 39 (Bergen) Senator  RAJ MUKHERJI District 32 (Hudson) Senator  HOLLY T. SCHEPISI District 39 (Bergen) Co-Sponsored by: Assemblyman Conaway, Assemblywoman Speight, Senator O'Scanlon, Assemblywoman Flynn and Assemblyman Scharfenberger SYNOPSIS Allows certain health care practitioners referrals to pharmacies to be made in accordance with certain professional standards. CURRENT VERSION OF TEXT As reported by the Senate Judiciary Committee on September 26, 2024, with amendments. An Act concerning health care practitioner referrals and amending P.L.1989, c.19. Be It Enacted by the Senate and General Assembly of the State of New Jersey: 1. Section 2 of P.L.1989, c.19 (C.45:9-22.5) is amended to read as follows: 2. a.  A practitioner shall not refer a patient or direct an employee of the practitioner to refer a patient to a health care service in which the practitioner, or the practitioner's immediate family, or the practitioner in combination with the practitioner's immediate family has a significant beneficial interest [;]except [that,] as follows: (1) in the case of a practitioner, a practitioner's immediate family, or a practitioner in combination with the practitioner's immediate family who had the significant beneficial interest prior to the effective date of P.L.1991, c.187 (C.26:2H-18.24 et al.) [, and] ; (2) in the case of a significant beneficial interest in a health care service that provides lithotripsy or radiation therapy pursuant to an oncological protocol that was held prior to the effective date of this section of P.L.2009, c.24 [,] ; and (3) in the case of a practitioner, a practitioner's immediate family, or a practitioner in combination with the practitioner's immediate family who 1[had] has1 a significant beneficial interest in a pharmacy 1[and whose application for a permit to operate a pharmacy site was approved prior to the effective date of this section] that is integrated with an oncology practice, that only dispenses medications exclusively to patients of that practice, and that complies with the additional requirements set forth in subsection d. of this section1, the practitioner may continue to refer a patient or direct an employee to do so if that practitioner discloses the significant beneficial interest to the patient. b. If a practitioner is permitted to refer a patient to a health care service pursuant to this section, the practitioner shall provide the patient with a written disclosure form, prepared pursuant to section 3 of P.L.1989, c.19 (C.45:9-22.6), and post a copy of this disclosure form in a conspicuous public place in the practitioner's office. c. The restrictions on referral of patients established in this section shall not apply to: (1) medical treatment or a procedure that is provided at the practitioner's medical office and for which a bill is issued directly in the name of the practitioner or the practitioner's medical office; (2) renal dialysis; (3) ambulatory surgery or procedures involving the use of any anesthesia performed at a surgical practice licensed by the Department of Health pursuant to subsection g. of section 12 of P.L.1971, c.136 (C.26:2H-12) or at an ambulatory care facility licensed by the Department of Health to perform surgical and related services or lithotripsy services, if the following conditions are met: (a) the practitioner who provided the referral personally performs the procedure; (b) the practitioner's remuneration as an owner of or investor in the practice or facility is directly proportional to the practitioner's ownership interest and not to the volume of patients the practitioner refers to the practice or facility; (c) all clinically-related decisions at a facility owned in part by non-practitioners are made by practitioners and are in the best interests of the patient; and (d) disclosure of the referring practitioner's significant beneficial interest in the practice or facility is made to the patient in writing, at or prior to the time that the referral is made, consistent with the provisions of section 3 of P.L.1989, c.19 (C.45:9-22.6); (4) medically-necessary intraoperative monitoring services rendered during a neurosurgical, neurological, or neuro-radiological surgical procedure that is performed in a hospital; (5) a value-based arrangement made in accordance with 42 C.F.R. 411.357(aa), a payment model authorized under a Medicare shared savings program pursuant to 42 U.S.C. s.1395jjj, or a demonstration operated by the Center for Medicare and Medicaid Innovation established pursuant to at 42 U.S.C. s.1315a; and (6) Referrals that a practitioner makes, or directs an employee of the practitioner to make, to a health care service in which the referring practitioner has a significant beneficial interest, when participants in an alternative payment model registered with the Department of Health pursuant to section 3 of P.L.2017, c.111 (C.45:9-22.5c) make a bona fide determination that: the significant beneficial interest is reasonably related to the alternative payment model standards filed with the Department of Health, provided that the determination is documented and retained for a period of 10 years; and the referral is made in accordance with alternative payment model standards and professional standards applicable to the health care service in which the referring practitioner has a significant beneficial interest. 1d. The exemption set forth in paragraph (3) of subsection a. of this section shall apply to a pharmacy that is integrated with an oncology practice, provided that the pharmacy: (1) has direct access to the oncology practices patient records; (2) communicates with each patient in person or via telemedicine to review the prescription instructions and assesses the patient for interactions with other drugs and food; (3) synchronously consults with the oncology practices treating physicians as appropriate; and (4) complies with the requirements for timely delivery of medications, hours of operation, and recordkeeping that are established by rule or regulation by the State Board of Pharmacy.1 (cf: P.L.2021, c.347) 2.  This act shall take effect immediately.